The role of hepatitis B vaccine challenge dose in patients with underlying health conditions

We have evaluated the immunological response to Hepatitis B virus (HBV) booster vaccine dose in 129 adults with underlying diseases in comparison with 694 subjects at occupational risk of infection, who have previously completed the primary series and resulted with anti-HBs <10 mIU/mL. After boos...

Descripción completa

Detalles Bibliográficos
Autores principales: Sticchi, L., Iavarone, I. G., Durando, P., Di Biagio, A., Schiavetti, I., Murgia, F., Icardi, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899643/
https://www.ncbi.nlm.nih.gov/pubmed/32614653
http://dx.doi.org/10.1080/21645515.2020.1777058
_version_ 1783654060746866688
author Sticchi, L.
Iavarone, I. G.
Durando, P.
Di Biagio, A.
Schiavetti, I.
Murgia, F.
Icardi, G.
author_facet Sticchi, L.
Iavarone, I. G.
Durando, P.
Di Biagio, A.
Schiavetti, I.
Murgia, F.
Icardi, G.
author_sort Sticchi, L.
collection PubMed
description We have evaluated the immunological response to Hepatitis B virus (HBV) booster vaccine dose in 129 adults with underlying diseases in comparison with 694 subjects at occupational risk of infection, who have previously completed the primary series and resulted with anti-HBs <10 mIU/mL. After booster dose, 60.5% of the patients with underlying diseases and 14.8% of the subjects at occupational risk resulted seronegative. By comparing two groups, rate of subjects with anamnestic response was higher in at occupational risk group respect to that at risk for medical conditions (OR: 5.99 [95%IC, 3.81–9.41], p < .001). This difference was associated to gender (males/females: OR: 0.619 [95%IC, 0.421–0.910], p = .015) and age (better response for younger people, p = .011).
format Online
Article
Text
id pubmed-7899643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78996432021-03-02 The role of hepatitis B vaccine challenge dose in patients with underlying health conditions Sticchi, L. Iavarone, I. G. Durando, P. Di Biagio, A. Schiavetti, I. Murgia, F. Icardi, G. Hum Vaccin Immunother Letter We have evaluated the immunological response to Hepatitis B virus (HBV) booster vaccine dose in 129 adults with underlying diseases in comparison with 694 subjects at occupational risk of infection, who have previously completed the primary series and resulted with anti-HBs <10 mIU/mL. After booster dose, 60.5% of the patients with underlying diseases and 14.8% of the subjects at occupational risk resulted seronegative. By comparing two groups, rate of subjects with anamnestic response was higher in at occupational risk group respect to that at risk for medical conditions (OR: 5.99 [95%IC, 3.81–9.41], p < .001). This difference was associated to gender (males/females: OR: 0.619 [95%IC, 0.421–0.910], p = .015) and age (better response for younger people, p = .011). Taylor & Francis 2020-07-02 /pmc/articles/PMC7899643/ /pubmed/32614653 http://dx.doi.org/10.1080/21645515.2020.1777058 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Letter
Sticchi, L.
Iavarone, I. G.
Durando, P.
Di Biagio, A.
Schiavetti, I.
Murgia, F.
Icardi, G.
The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title_full The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title_fullStr The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title_full_unstemmed The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title_short The role of hepatitis B vaccine challenge dose in patients with underlying health conditions
title_sort role of hepatitis b vaccine challenge dose in patients with underlying health conditions
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899643/
https://www.ncbi.nlm.nih.gov/pubmed/32614653
http://dx.doi.org/10.1080/21645515.2020.1777058
work_keys_str_mv AT sticchil theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT iavaroneig theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT durandop theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT dibiagioa theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT schiavettii theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT murgiaf theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT icardig theroleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT sticchil roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT iavaroneig roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT durandop roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT dibiagioa roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT schiavettii roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT murgiaf roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions
AT icardig roleofhepatitisbvaccinechallengedoseinpatientswithunderlyinghealthconditions

Ejemplares similares